Compare Ambarella Inc (AMBA) vs Cardinal Health Inc (CAH) Price & Performance

Ambarella (AMBA) trades at $77.30, down 1.38% on the day, with a bullish technical setup supported by moving averages and key resistance at $81. The company reported three consecutive quarterly EPS beats, with Q1 2027 earnings of $0.11 meeting estimates, while revenue grew 16.9% year-over-year to $100.4 million. A major catalyst is the $800+ million long-term edge AI agreement with Hanwha, signaling strong demand in physical AI markets. However, net income remains negative at -$117.13 million for 2025, though margins are improving.

Outlook: Wall Street is bullish with a $108.67 consensus price target (40% upside), driven by edge AI adoption and auto sector growth. Risks include persistent losses, competitive pressure from larger chipmakers, and execution challenges in scaling new AI contracts. The stock's valuation at 8.21x sales appears reasonable if revenue acceleration continues, but profitability remains key for sustained gains.

Cardinal Health (CAH) trades at $235.80, up 0.87% with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with 37.08% ROE and positive revenue growth trends from $222.58B in 2025 to projected $250.7B in 2026. Recent removal from Russell indices has not dampened analyst optimism, with 54.55% maintaining buy ratings and a $248 consensus price target representing 5% upside potential.

The outlook remains positive given CAH's defensive healthcare distribution business and specialty pharma expansion. Key risks include negative shareholder equity of -$3.21B and elevated debt levels with 16.09% debt-to-asset ratio. Earnings momentum from three consecutive quarterly beats supports the bullish case, though investors should monitor the upcoming Q2 2026 results against $2.41 EPS expectations.